We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Lexology logo






  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 10

Outside of FDA

  • Drinker Biddle & Reath LLP
  • -
  • Canada, European Union
  • -
  • April 30 2008

Health Canada has issued a draft guidance Information and Submission Requirements for Subsequent Entry Biologics (SEBs

Exchange of confidential information between the European Commission and Health Canada

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, European Union
  • -
  • January 17 2008

The European Commission's Directorate-General Enterprise and Industry, the European Medicines Agency (EMEA), and the Health Products and Food Branch of Health Canada have recently concluded confidentiality agreements which will allow the following types of information to be shared between these authorities, in the area of medicines and therapeutic product regulation

European Union - Canada debate IP rights for pharmaceuticals

  • Norton Rose Canada LLP
  • -
  • Canada, European Union
  • -
  • July 12 2011

This briefing written at the invitation of Canada's Research-Based Pharmaceutical Companies (Rx&D) provides a further contribution to the current debate around IP rights for pharmaceuticals in Canada

CETA trade negotiations 2011 drug market exclusivity in the EU and Canada

  • Norton Rose LLP
  • -
  • Canada, European Union
  • -
  • October 21 2011

A consideration of why Canada should answer the European Union’s call for heightened IP protection for pharmaceuticals

Europe discards embryonic stem cell patents

  • Bereskin & Parr LLP
  • -
  • Canada, European Union
  • -
  • December 15 2011

Adult stem cells, and processes for their manipulation, are generally patentable in Europe

Methods of medical treatment claims issues in Canada, US and Europe

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, European Union, USA
  • -
  • November 30 2012

In this presentation, Scott Foster and Konrad Sechley address methods of medical treatment claims issues in Canada, US and Europe

Life sciences & law current issues 201213

  • Gowling Lafleur Henderson LLP
  • -
  • Canada, European Union, USA
  • -
  • June 18 2012

Each stage of the life cycle of a company or a product presents challenges that demand the expertise and resources of a strong legal partner

Biosimilar battlegrounds - what is new in biosimilars and where?

  • Bereskin & Parr LLP
  • -
  • Canada, European Union, USA
  • -
  • February 17 2012

Biosimilars are second entry biologic drugs

Universities abroad experiment with no-fee licensing to drive biotech partnerships

  • Shook Hardy & Bacon LLP
  • -
  • Australia, Canada, European Union, United Kingdom, USA
  • -
  • May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies

Dispelling the Myriad gene patent harmonization myth

  • Foley & Lardner LLP
  • -
  • Australia, Canada, European Union, France, Germany, Japan, USA
  • -
  • April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction

Workarea

© Copyright 2006-2013 Globe Business Publishing Ltd | Cookies | Disclaimer | Privacy policy